(±)-Methadone-d3 (CRM) is intended for use as an internal standard for the quantification of methadone by GC- or LC-MS. (±)-Methadone is categorized as an opioid.[1] It has analgesic activity.[2] Formulations containing (±)-methadone have been used in the treatment of opioid addiction. (±)-Methadone-d3 is regulated as a Schedule II compound in the United States. (±)-Methadone-d3 (CRM) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.
References:
[1].Raynor, K., Kong, H., Chen, Y., et al.Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptorsMol. Pharm.45(2)330-334(1994).
[2].He, L., Kim, J., Ou, C., et al.Methadone antinociception is dependent on peripheral opioid receptorsJ. Pain.10(4)369-379(2009).